XML 85 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACQUISITIONS (Details) (USD $)
 3 Months Ended
Jun. 30, 2012
Jun. 29, 2013
Sep. 29, 2012
Hemerus Medical, LLC [Member]
      
Business Acquisition [Line Items]      
Business acquisition, cash paid $ 1,000,000 $ 23,100,000  
Asset class      
Intangible assets   20,400,000  
Goodwill   10,324,000  
Fair value of net assets acquired   30,724,000  
Pall Corporation [Member]
      
Asset class      
Inventories   49,917,000  
Property, plant and equipment   84,704,000  
Intangible assets   188,500,000  
Other assets/liabilities, net   (6,266,000)  
Goodwill   218,320,000  
Fair value of net assets acquired   535,175,000  
Business acquistion, cost of aquired entity     535,200,000
Business acquisition, additional anticipated payment     15,000,000
Business Acquisition, Pro Forma Information [Abstract]      
Net sales 230,425,000    
Net income 14,217,000    
Basic earnigs per share (in dollars per share) $ 0.28    
Diluted earnigs per share (in dollars per share) $ 0.27    
Amortization of acquired intangible assets 3,927,000 [1]    
Interest expense incurred on acquisition financing 2,380,000 [2]    
Selling, general and admin expenses 2,635,000 [1]    
Purchase Price Allocation Adjustments [Member] | Pall Corporation [Member]
      
Asset class      
Property, plant and equipment     (1,300,000)
Other assets/liabilities, net     100,000
Goodwill     1,400,000
FDA Approval of SOLX [Member] | Hemerus Medical, LLC [Member]
      
Business Acquisition [Line Items]      
Contingent consideration, maximum   3,000,000  
Future Sales of SOLX [Member] | Hemerus Medical, LLC [Member]
      
Business Acquisition [Line Items]      
Contingent consideration, maximum   $ 14,000,000  
[1] Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis.
[2] Added additional interest expense for the debt used to finance the acquisition.